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AIMS
To investigate whether the use of carbamazepine is associated with
reduced risk of Parkinson’s disease.
METHODS
We conducted a population-based, matched case–control study of
patients randomly selected from the UK General Research Practice
Database. We identified 8549 patients with Parkinson’s disease using
diagnosis criteria with a positive predictive value of 90%. These
patients were compared with 42 160 control subjects matched for age,
sex and general practice.
RESULTS
Overall, 3.0% of cases (257 of 8549) had at least one recorded
prescription for carbamazepine compared with 2.5% (1050 of 42 160)
of controls. The crude odds ratio for the association between
Parkinson’s disease and carbamazepine was 1.22 (95% confidence
interval 1.06–1.40), but this reduced to 0.93 (95% confidence interval
0.81–1.08, P = 0.34) after adjusting for annual consultation rate. Further
adjustment for body mass index, smoking status, alcohol consumption
or use of calcium channel blockers did not affect results. There was no
evidence that risk decreased with higher doses or longer duration of
carbamazepine use.
CONCLUSIONS
There was little to no evidence that use of carbamazepine is associated
with reduced risk of Parkinson’s disease. Although the study was
underpowered, it does indicate that any effect of carbamazepine is
likely to be small.
WHAT IS ALREADY KNOWN ABOUT
THIS SUBJECT
• Parkinson’s disease is associated with the
intracellular accumulation of Lewy bodies,
which are abnormal protein aggregations
comprising misfolded a-synuclein protein.
• Carbamazepine has been identified as a
drug candidate that may enhance
intracellular autophagy and the clearance of
these mutant proteins.
• It is unknown whether use of this drug is
associated with reduced risk of Parkinson’s
disease.
WHAT THIS STUDY ADDS
• There is little evidence that use of
carbamazepine is associated with reduced
risk of Parkinson’s disease, although a
modest protective effect cannot be
excluded.
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Introduction
Parkinson’s disease (PD) is a neurodegenerative disorder
that is clinically characterized by symptoms of tremor,
rigidity, bradykinesia and postural instability [1]. These
abnormal motor functions are due to degeneration of
dopaminergic neurons, which some have theorized is a
result of intracellular accumulation of Lewy bodies [2, 3].
Lewy bodies are abnormal protein aggregations com-
prising misfolded a-synuclein protein [3, 4]. The process
which normally rids cells of these abnormal proteins is
called autophagy, and its role in degrading toxic proteins
has been recognized only recently [5]. Autophagy occurs
when membranous structures called autophagosomes
form around intracytosolic proteins or other structures
and the contents are degraded by lysosomes [6]. Recent
research has focused on identifying drugs which can
modify autophagy, with the hope that drugs which stimu-
late the process could be used as treatments for neurode-
generative disorders. A number of autophagy-inducing
compounds have been identified, one of which is the anti-
epileptic drug carbamazepine [7].
Recent studies indicate that carbamazepine operates in
a dose-dependent manner to increase autophagy in mice
to amplify the degradation of mutant liver proteins [8].The
documented autophagy-enhancing properties of car-
bamazepine make it a prime candidate for treating or pre-
venting PD. To date, no studies in humans have examined
whether use of carbamazepine is associated with develop-
ment of PD. We therefore used the UK General Practice
Research Database (GPRD) to perform a large, matched
case–control study to explore the risk of PD associated
with exposure to carbamazepine.
Methods
The General Practice Research Database
The General Practice Research Database is the largest elec-
tronic database of general practice (GP) clinical records in
the world and is a well-validated database for drug safety
and effectiveness research [9, 10]. It contains information
on demographic characteristics, diagnoses, prescriptions,
clinical tests, immunizations and hospital referrals for
nearly 9 million patients and has more than 50 million
patient-years of follow-up [9]. Patients participating in the
GPRD are representative of the UK with regard to age, sex
and geographic distribution.The GPRD is held by the Clini-
cal Practice Research Datalink, a research and data services
provider, which is jointly funded by the Medicines and
Healthcare products Regulatory Agency of the UK (MHRA)
and the UK National Institute for Health Research [9]. The
MHRA regularly monitors GPRD data [11], and several
studies have found it to be of high quality [5]. To date, the
GPRD has been the source of over 900 published studies.
Selection of participants
This was a large-scale, matched case–control study of
GPRD-registered patients. Cases were defined as all
patients with at least one diagnostic record of PD, who
were registered in the GPRD between 1990 and 2008, and
who had at least 1 year of research-standard follow-up
time before the first diagnosis.The index date for each case
was the date of the first diagnosis of PD. A patient was
excluded as a case if the date of diagnosis was unknown, if
antipsychotic medications were prescribed less than 6
months prior to being diagnosed with PD (because they
can induce PD-like symptoms [12]), if the case was a tem-
porary resident of the UK or if secondary causes of PD were
indicated. Patients with any of the following diagnoses
were treated as having secondary causes of PD: syphilitic
parkinsonism, postencephalitic parkinsonism, drug-
induced parkinsonism, secondary parkinsonism due to
other external agents, secondary parkinsonism, unspeci-
fied, or iatrogenic parkinsonism. Furthermore, cases were
required to have at least two prescriptions for any PD
therapies to increase the likelihood that the PD diagnosis
was valid.
Controls were selected from patients registered in the
GPRD and were matched in a 5:1 ratio to cases on age at
index date (5 years), sex and general practice. In order to
be eligible, controls must have had at least 1 year of
research-standard follow-up time prior to the index date of
the corresponding case.
Data extraction and analysis
All data management and statistical analyses were per-
formed using Stata (version 11; StataCorp LP, College
Station, TX, USA). Data were extracted from electronic
records, and analyses were limited to drug exposures
recorded before the index date. Drug exposure was
defined as ‘ever’ or ‘never’ based on prescription histories
prior to the index date. Patients with one or more prescrip-
tions were included in the‘ever’exposure category. Median
daily doses of carbamazepine were calculated for all
exposed patients based on extracted daily dose informa-
tion and were categorized as follows:200 mg day-1;>200
to 400 mg day-1; and >400 mg day-1. The cumulative
dose was also calculated for each exposed patient. The
three levels of cumulative exposure to carbamazepine
were as follows: <30 000 mg; 30 000 to <300 000 mg;
and 300 000 mg. Notably, many exposed patients had
missing daily dose values. These missing values were
imputed in one of the following two ways: if possible, a
patient’s missing daily dose information was predicted
from previous prescribing history; if this was not possible,
the patient was treated as having the median daily dose
associated with the specific drug prescribed (e.g. all sub-
jects with missing daily dose values for Tegretol 100 mg
tablets were assigned a daily dose of three tablets, the
median daily dose for all individuals prescribed this drug).
Lastly, prescription dates were extracted and used to
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calculate the duration of treatment, which was categorized
as <1 year,1 to 5 years or >5 years.
Data were also extracted on the following potentially
confounding variables, all of which were selected based on
known or expected associations with Parkinson’s disease:
body mass index (BMI) [13]; smoking status [14, 15]; alcohol
consumption [14]; use of calcium channel blockers [5];
and annual consultation rate (a measure of help-seeking
behaviour defined as the number of times a patient initi-
ated contact with a GP surgery in the 12 months prior to
the index date). Consultation rate was considered for
adjustment because patients who receive carbamazepine
may have higher rates of consultation, which may also
increase the opportunity for recording other diagnoses,
such as PD.
Descriptive analyses were performed to tabulate the
distribution of demographic characteristics and poten-
tially confounding variables among cases and controls.
Conditional logistic regression was used to assess expo-
sure variables as confounders if they were associated with
both carbamazepine exposure and PD. Conditional logistic
regression models were built using a forward stepwise
approach. Potentially confounding exposure variables
were added to the model one by one, starting with the
variable with the largest confounding effect. Confounding
variables were kept in the model only if inclusion appreci-
ably changed the effect of carbamazepine exposure on PD.
Sensitivity analyses
Sensitivity analyses were conducted for the following
reasons: (i) to assess the effect of imputing missing data; (ii)
to explore the impact of treating patients with fewer than
two prescriptions as ‘unexposed’; (iii) to assess the effect of
misclassification of the outcome by reclassifying some
cases as controls and vice versa; and (iv) to assess the
impact of misclassification of the duration of exposure by
reclassifying patients with fewer than 5 years of car-
bamazepine exposure as ‘unexposed.’
Power
Power calculations were performed in Excel based on a
formula by Schlesselman [16] and used the prevalence of
the drug exposure among controls in this study and an
a level of 0.05. Calculations indicated that with five con-
trols per case, this study had at least 80% power to detect
a 20% reduction in PD due to use of carbamazepine.
Ethical approval was received from the London School
of Hygiene and Tropical Medicine Research Ethics Commit-
tee and the Independent Scientific Advisory Committee
for the MHRA.
Results
A total of 8549 patients with PD were included in the study
and matched with 42 160 control patients.Table 1 displays
the age and sex distribution of cases and controls, their
BMI, smoking status, alcohol consumption status, use of
calcium channel blockers and annual consultation rate.
Smoking status, alcohol consumption and BMI were
missing for some patients. Patients with missing data for
covariates were analysed as separate strata. Sensitivity
analyses in which missing data were imputed using multi-
ple imputations by chained equations [17] showed no
material differences in univariable estimates.
The majority (57.7%) of cases were male, and the
median age of study patients was 75 years.The median BMI
for all patients was 25.6 kg m–2, and cases had slightly
lower median BMI than controls (25.2 vs. 25.8 kg m–2).
There was strong evidence that current and ex-smokers
had a lower risk of PD compared with nonsmokers [odds
ratio (OR) for current smokers 0.46, 95% confidence inter-
val (CI) 0.43–0.50], which is consistent with previous find-
ings [14, 15]. Increasing alcohol consumption was also
associated with reduced risk of diagnosis of PD (Table 1),
but there was little evidence of an association between use
of calcium channel blockers and PD (OR 1.02, 95% CI 0.96–
1.08). As expected, cases had a substantially higher median
annual consultation rate than controls (21 vs. 15 GP con-
tacts year–1), and patients in the highest consultation rate
quintile had almost eight times the odds of being diag-
nosed with PD as patients in the lowest quintile (OR 7.73,
95% CI 6.98–8.56). The median duration of follow-up time
for cases and controls was nearly identical (7.58 vs. 7.61
years, respectively).
Table 2 displays the associations between diagnosis of
PD and exposure to carbamazepine. Among cases, 3.0%
(257 of 8549) had at least one recorded prescription for
carbamazepine in comparison to 2.5% (1050 of 42 160) of
controls.
The crude odds ratio for the association between ‘ever’
use of carbamazepine and a diagnosis of Parkinson’s
disease was 1.22 (95% CI 1.06–1.40). The association was
diminished after adjusting for annual consultation rate,but
it was not affected by further adjustment for BMI, smoking
status, alcohol consumption or use of calcium channel
blockers. After adjusting for annual consultation rate, the
odds ratio for the association between carbamazepine use
and PD diagnosis was 0.93 (95% CI 0.81–1.08, P = 0.34).
There was little evidence that the association differed by
duration (P = 0.46), cumulative dose (P = 0.38) or daily dose
of carbamazepine (P = 0.17). Results from the sensitivity
analysis that reclassified people with two or fewer car-
bamazepine prescriptions as unexposed were comparable
to those of the primary analysis.
Additional sensitivity analyses and
model checking
The criteria we used for diagnosing patients with PD have
a positive predictive value of 90% [5]. We therefore per-
formed a sensitivity analysis in which we reclassified 10%
of cases as controls, assuming that the misclassification
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would be nondifferential with respect to exposure status.
We also performed a sensitivity analysis in which we reclas-
sified 0.634% of controls as cases (the calculated mean
European prevalence of PD [18]), assuming that the mis-
classification would be nondifferential with respect to
exposure status. In both instances, the crude odds ratios
were not materially different from primary analyses.
Given that the the onset of PD could occur several years
before the onset of symptoms, we performed a sensitivity
analysis in which we reclassified patients with fewer than
5 years of carbamazepine exposure as ‘unexposed’. This
analysis yielded results that were consistent with the
primary analysis.
In primary analyses, adjusting for consultation rate
reduced the association between carbamazepine use and
PD. We propose that this reduction occurred because con-
sultation rate is a measure of help-seeking behaviour and
current illness, and people who frequently contact or
attend their GP surgery for either reason are likely to
receive earlier diagnosis of PD by virtue of being seen by a
clinician more often. However, it is also plausible that car-
bamazepine use itself increases the risk of PD, and as
patients exposed to carbamazepine develop symptoms of
PD they increase their rate of consultation with the GP. If
this were the case, it would be inappropriate to adjust for
consultation rate. To explore this, we examined the clinical
records of a random sample of 20 PD cases with high con-
sultation rates (top quintile), half whom were exposed to
carbamazepine. We looked for consultations relating to
neurological conditions, including conditions that are
Table 1
Characteristics of cases and controls: univariable associations between exposures and Parkinson’s disease
Characteristic
Cases (%)
n = 8549
Controls (%)
n = 42 160
Univariable odds ratio
(95% confidence interval)
Age*
<60 years 796 (9.3) 3967 (9.4) –
60–69 years 1770 (20.7) 8751 (20.8) –
70–79 years 3451 (40.4) 17 013 (40.4) –
80 years 2532 (29.6) 12 429 (29.5) –
Sex*
Male 4940 (57.8) 24 292 (57.6) –
Female 3609 (42.2) 17 868 (42.4) –
Body mass index (kg m-2)
<18.5 234 (2.7) 801 (1.9) 1
18.5–24.9 3044 (35.6) 13 720 (32.5) 0.76 (0.67–0.83)
25–29.9 2592 (30.3) 14 051 (33.3) 0.63 (0.57–0.70)
30 969 (11.3) 6271 (14.9) 0.53 (0.47–0.59)
Unknown 1710 (20.0) 7317 (17.4) 0.80 (0.75–0.93)
Smoking status
Nonsmoker 4539 (53.1) 17 801 (42.2) 1
Current smoker 760 (8.9) 6153 (14.6) 0.46 (0.43–0.50)
Ex-smoker 2680 (31.4) 15 548 (36.9) 0.64 (0.61–0.68)
Unknown 570 (6.7) 2658 (6.3) 0.84 (0.76–0.93)
Alcohol consumption
Nondrinker 1235 (14.5) 5708 (13.5) 1
Ex-drinker 158 (1.9) 583 (1.4) 1.25 (1.03–1.51)
Current drinker (unknown amount) 205 (2.4) 936 (2.2) 1.01 (0.86–1.20)
<2 units day-1 4891 (57.2) 24 307 (57.7) 0.92 (0.85–0.99)
3–6 units day-1 651 (7.6) 3904 (9.3) 0.74 (0.67–0.83)
>6 units day-1 68 (0.80) 452 (1.1) 0.67 (0.52–0.88)
Unknown 1341 (15.7) 6270 (14.9) 0.99 (0.90–1.08)
Use of calcium channel blockers
Never 5740 (67.1) 28 751 (68.2) 1
Ever 2809 (32.9) 13 409 (31.8) 1.02 (0.96–1.08)
Consultation rate
<6 contacts year-1 600 (7.0) 9497 (22.5) 1
6–12 contacts year-1 1373 (16.1) 8631 (20.5) 2.79 (2.52–3.09)
13–18 contacts year-1 1601 (18.7) 7768 (18.4) 3.98 (3.59–4.41)
19–27 contacts year-1 2194 (25.7) 8086 (19.2) 5.62 (5.08–6.22)
28 contacts year-1 2781 (32.5) 8178 (19.4) 7.73 (6.98–8.56)
Median annual consultation rate (interquartile range) 21 contacts year-1 (13–31) 15 contacts year-1 (6–24) –
Median follow-up time prior to index date (interquartile range) 7.6 years (4.1–11.1) 7.6 years (4.1–11.1) –
*Matched variable.
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indications for carbamazepine, such as epilepsy, pain and
mood disturbances. These events accounted for 9.5% of
consultations amongst unexposed cases and 8.4% of con-
sultations amongst exposed cases. There was no excess of
these events amongst exposed cases, which supports our
theory that increased surveillance, rather than use of car-
bamazepine, better explains the higher rates of PD diag-
nosis that were observed among patients with high
consultation rates.
Discussion
We found little evidence that carbamazepine is associated
with a reduced risk of Parkinson’s disease diagnosis.
Despite this, our finding of a 7% reduction in odds of PD
associated with use of carbamazepine, although not statis-
tically significant, is consistent with the findings of Hidvegi
et al. [8], who found that in a mouse model, carbamazepine
promoted the reduction of mutant protein aggregations in
the liver by increasing the rate of intracellular autophagy.
Adjusting for annual consultation rate reduced the
crude odds ratio.We believe this adjustment was appropri-
ate because the likelihood of receiving a prescription for
carbamazepine and the diagnosis of PD were both related
to the frequency of consultation. When compared with
patients in the lowest consultation rate group, patients in
the highest group had almost seven times the odds of
receiving carbamazepine prescriptions. Moreover, the
odds of a PD diagnosis were 7.73 times higher (95% CI
6.98–8.56) in these patients compared with those in the
lowest consultation rate group. These results are logically
consistent with what probably occurs at the GP; people
exposed to carbamazepine have serious medical condi-
tions, which would require them to attend the GP more
often than a healthy person. This frequent attendance is
likely to result in earlier diagnosis of PD for these individu-
als. This early diagnosis explains why, after adjusting for
annual consultation rate, the effect estimate for car-
bamazepine was reduced. Although sensitivity analyses
provided support for this theory, we cannot rule out the
possibility that the observed increase in consultation rates
reflect an increased risk of Parkinson’s disease caused by
carbamazepine use. This is an acknowledged limitation of
our results.
This study is the first of its kind to examine the associa-
tion between diagnosis of Parkinson’s disease and expo-
sure to carbamazepine. Its strengths lie in its setting and
design; it was a very large, population-based case–control
study, with controls matched for age, sex and general prac-
tice. Additionally, because the geographic and demo-
graphic profile of patients enrolled in the GPRD are
representative of the UK population, our findings should
be generalizable to the UK as a whole.
Other strengths include the quality of exposure and
outcome data.The GPRD contains very detailed drug expo-
sure information, including drug name, dosage, dose fre-
quency, prescription date and prescription duration, and
the accuracy of these data collected in the GPRD has been
validated [19]. The outcome data in this study are also reli-
able. The validity of GPRD diagnoses was recently exam-
ined by a systematic review, which found that 89% of all
diagnoses were confirmed by additional review [10]. With
respect to PD diagnoses in particular, among patients with
Table 2
Associations between exposure to carbamazepine and diagnosis of Parkinson’s disease
Drug exposure
Cases (%)
n = 8549
Controls (%)
n = 42 160
Crude odds ratio (95%
confidence interval)
Adjusted odds ratio *
(95% confidence interval) P value
Carbamazepine
Never 8292 (97.0) 41 110 (97.5) 1 1
Ever 257 (3.0) 1050 (2.5) 1.22 (1.06–1.40) 0.93 (0.81–1.08) 0.34
Carbamazepine duration
Never 8292 (97.0) 41 110 (97.5) 1 1 0.46
<1 year 147 (1.7) 660 (1.6) 1.11 (0.93–1.33) 0.87 (0.72–1.04)
1–5 years 56 (0.66) 204 (0.48) 1.36 (1.01–1.83) 0.99 (0.73–1.34)
>5 years 54 (0.63) 186 (0.44) 1.44 (1.06–1.96) 1.09 (0.80–1.49)
Carbamazepine cumulative dose (mg ¥ 103)
Never 8292 (97.0) 41 110 (97.5) 1 1 0.38
<30 132 (1.5) 606 (1.4) 1.09 (0.99–1.32) 0.85 (0.70–1.04)
30–299 66 (0.77) 244 (0.58) 1.34 (1.02–1.76) 1.02 (0.77–1.34)
300 59 (0.69) 200 (0.47) 1.46 (1.09–1.96) 1.08 (0.80–1.45)
Carbamazepine median daily dose (mg ¥ 103)
Never 8292 (97.0) 41 110 (97.5) 1 1 0.17
200 116 (1.4) 548 (1.3) 1.05 (0.86–1.29) 0.81 (0.66–0.99)
201–400 103 (1.2) 352 (0.83) 1.46 (1.17–1.82) 1.10 (0.86–1.38)
>400 38 (0.44) 150 (0.36) 1.26 (0.88–1.80) 1.00 (0.69–1.45)
*Adjusted for consultation rate quintile.
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at least two prescriptions for PD, 90% of GRPD diagnoses of
PD were confirmed by a review of medical records [5].What
we do not know, however, is the number of individuals
with PD who were not picked up by our search criteria (e.g.
false negatives); we are therefore unable to draw firm
conclusions about the sensitivity of our case definition.
However, sensitivity analyses indicated that minor misclas-
sification would have little to no effect on our findings.
In spite of its size, the main weakness of our study was
its inability to detect small reductions in risk.The 95% con-
fidence intervals for the adjusted odds ratio for the asso-
ciation between ‘ever’ use of carbamazepine and PD
diagnosis indicate that the data are consistent with an
effect ranging from an odds ratio of 0.81 to 1.08. However,
because so few study participants were exposed to car-
bamazepine, our study was underpowered to detect such
small effects.
Another limitation is that because the symptoms of PD
appear only after 50–70% of dopaminergic neurons are
lost, it is possible that there are a number of undiagnosed,
asymptomatic patients [20]. It is therefore plausible that
some controls with early stage PD were not identified as
cases. However, owing to the rarity of PD only a small
number of controls would be affected by this, and there is
no reason to suspect that this type of misclassification
would have been differential with respect to exposure
status.The scope of this type of misclassification was there-
fore likely to be minimal. Moreover, sensitivity analyses
indicated that if this misclassification occurred, the effect
would be negligible.
One of the limitations of examining drug effects using
the GPRD is the uncertainty regarding drug exposure.
Given that there are no assurances that patients took their
prescribed medication, there is always the potential for
misclassification of exposure. The potential for exposure
misclassification in this study was amplified by the fact that
8.1% (2035 of 25 164) of carbamazepine daily dose values
were missing and imputed. Our results showed that a
higher proportion of cases than controls had at least one
missing daily dose value for carbamazepine: 22.6 vs. 16.5%
(P = 0.02). If the imputed missing daily dose values did not
reflect actual prescription information, then the estimates
of effect in this study could be biased. Moreover, this study
accounted only for drug received while patients were reg-
istered at a GPRD-participating clinic. It is therefore possi-
ble that some patients were exposed prior to registration
and this information was not recorded.However,given that
the majority of carbamazepine prescribing is through
primary care in the UK, the scope for bias from such mis-
classification is likely to be low.
An additional limitation of using GPRD data is that the
indication for use is not explicitly linked to each drug pre-
scribed by a clinician. The likely indication can be inferred
from the clinical diagnostic codes recorded around the
time of the drug prescription, but the accuracy of these
inferences cannot be guaranteed.
There is also a possibility that the variables estimating
duration of treatment did not accurately reflect the length
of time for which patients were exposed to a drug. Treat-
ment duration was calculated by measuring the time
elapsed between first and last prescriptions for a drug.This
method was chosen over alternative methods in order
to avoid generating biased estimates based on imputed
daily dose data (alternative methods involve dividing the
number of pills dispensed by the prescribed daily dose to
achieve the number of days per prescription; then all pre-
scription durations are summed to provide an overall dura-
tion of drug for each patient).However,our chosen method
of measurement precludes the ability to take into account
any gaps in treatment (i.e. periods of non-exposure). As a
result, an inherent limitation of the duration exposure vari-
able is that some individuals with long periods of time
between only a few prescriptions will be misclassified as
having a long period of exposure.This could impact results.
For example, if the risk of PD does decrease with duration
of treatment with carbamazepine, and if a portion of the
patients in the longest duration group were actually
exposed to the drug for only a short period of time, then
the result would be to bias the odds ratio towards the null
in the highest duration group. However, the data do not
support an inference of misclassification among patients
in the higher duration groups; of the 240 participants
exposed to carbamazepine for more than 5 years, only 10
(4.2%) were in the lowest cumulative exposure group
(<30 000 mg).
Conclusion
Our analyses found little to no evidence that use of car-
bamazepine is associated with reduced risk of Parkinson’s
disease. Even though the observed 7% reduction in risk
associated with carbamazepine use is not inconsistent
with a protective effect given the limited power of our
study, the lack of any association with either total or
average dose suggests that a protective role for car-
bamazepine is unlikely. It is therefore infeasible to recom-
mend carbamazepine as a preventive measure for PD. Our
findings do not, however, preclude the possibility that
other drugs have the potential to treat PD. Future studies
should continue to examine the effects of autophagy-
enhancing compounds on development of Parkinson’s
disease.
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